A Novel Adc Targeting Cell Surface Fibromodulin in a Mouse Model of Triple-Negative Breast Cancer Publisher Pubmed



Haji Ghaffari M¹ ; Simonian M² ; Salimi A² ; Mirzadegan E³ ; Sadeghi N² ; Nejadmoghaddam MR² ; Ebrahimnezhad N² ; Fazli G² ; Fatemi R² ; Bayat AA² ; Mazloomi M¹ ; Rabbani H² Show Affiliations
Source: Breast Cancer Published:2022

Abstract

Background: Triple-negative breast cancers (TNBCs) are highly aggressive and metastatic. To date, finding efficacious targeted therapy molecules might be the only window of hope to cure cancer. Fibromodulin (FMOD), is ectopically highly expressed on the surface of Chronic Lymphocytic Leukemia (CLL) and bladder carcinoma cells; thus, it could be a promising molecule for targeted therapy of cancer. The objective of this study was to evaluate cell surface expression of FMOD in two TNBC cell lines and develop an antibody–drug conjugate (ADC) to target FMOD positive TNBC in vitro and in vivo. Materials and methods: Two TNBC-derived cell lines 4T1 and MDA-MB-231 were used in this study. The specific binding of anti-FMOD monoclonal antibody (mAb) was evaluated by flow cytometry and its internalization was verified using phAb amine reactive dye. A microtubulin inhibitor Mertansine (DM1) was used for conjugation to anti-FMOD mAb. The binding efficacy of FMOD-ADC was assessed by immunocytochemistry technique. The anti-FMOD mAb and FMOD-ADC apoptosis induction were measured using Annexin V-FITC and flow cytometry. Tumor growth inhibition of anti-FMOD mAb and FMOD-ADC was evaluated using BALB/c mice injected with 4T1 cells. Results: Our results indicate that both anti-FMOD mAb and FMOD-ADC recognize cell surface FMOD molecules. FMOD-ADC could induce apoptosis in 4T1 and MDA-MB-231 cells in vitro. In vivo tumor growth inhibition was observed using FMOD-ADC in 4T1 inoculated BALB/c mice. Conclusion: Our results suggests high cell surface FMOD expression could be a novel bio-marker TNBCs. Furthermore, FMOD-ADC could be a promising candidate for targeting TNBCs. © 2022, The Author(s), under exclusive licence to The Japanese Breast Cancer Society.